◎ Sugi Atlas

Atlas / Drug / Maxacalcitol

Maxacalcitol

drug
On this page

Also known as OCTOxarolPreziosSCH 209579SCH-209579SCH209579SID144206553

Summary

Maxacalcitol (CHEMBL333950) is a phase-3 clinical-stage small molecule targeting VDR; indicated across 1 condition including secondary hyperparathyroidism.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (VDR)
  • Indications: 1 condition
  • Clinical trials: 52
  • Chemistry: 418.6 Da · C26H42O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL333950
NameMaxacalcitol
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID6398761
Molecular formulaC26H42O4
Molecular weight418.6
InChIKeyDTXXSJZBSTYZKE-ZDQKKZTESA-N

SMILES: C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O

IUPAC name: trans-(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

Also known as: Maxacalcitol, OCT, Oxarol, Prezios, SCH 209579, SCH-209579, SCH209579, maxacalcitol, MAXACALCITOL, SID144206553

Patent coverage: 519 distinct patent families (1,797 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
VDRVitamin D receptorAgonist8.210.2%P11473

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Vitamin D3 receptor.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
VDR9.07EC500.85nMCHEMBL_ACT_16635831
VDR7.42EC5037.9nMCHEMBL_ACT_15730667
VDR7.39EC5040.8nMCHEMBL_ACT_15730691
VDR6.84EC50144.5nMCHEMBL_ACT_16635836
VDR6.8EC50159.7nMCHEMBL_ACT_16635841

Target pathways

Aggregated over 1 target gene(s): VDR.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Vitamin D (calciferol) metabolism1VDR
Nuclear Receptor transcription pathway1VDR
SUMOylation of intracellular receptors1VDR

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
cell morphogenesis1
skeletal system development1
calcium ion transport1
intracellular calcium ion homeostasis1
lactation1
negative regulation of cell population proliferation1
positive regulation of gene expression1
negative regulation of keratinocyte proliferation1
cell differentiation1
positive regulation of bone mineralization1
intracellular receptor signaling pathway1
phosphate ion transmembrane transport1
nuclear receptor-mediated bile acid signaling pathway1
mRNA transcription by RNA polymerase II1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
secondary hyperparathyroidism3MONDO:0006964EFO:1001173

Clinical trials

Total trials: 52.

Phase distribution

PhaseTrials
Not specified45
PHASE43
PHASE22
PHASE2/PHASE31
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06372925PHASE4RECRUITINGIntravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT02868203PHASE4UNKNOWNOCT Based Edge and In-stent Vascular Response After Cordimax Stent in patIents With NSTE-ACS
NCT05135312PHASE4UNKNOWNEtanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
NCT00764738PHASE2/PHASE3COMPLETEDStudy Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
NCT01341782PHASE3COMPLETEDComparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
NCT00667576PHASE2COMPLETEDDose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
NCT00990704PHASE2COMPLETEDParicalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
NCT02270359Not specifiedACTIVE_NOT_RECRUITINGResearch on Infarction With Open Arteries Using OCT and CMR
NCT02905357Not specifiedACTIVE_NOT_RECRUITINGHeart Attack Research Program- Imaging Study
NCT04737616Not specifiedACTIVE_NOT_RECRUITINGContinuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy
NCT05424705Not specifiedACTIVE_NOT_RECRUITINGPrediction of Atherosclerotic Plaque Progression
NCT06274593Not specifiedRECRUITINGStudy of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
NCT06349538Not specifiedENROLLING_BY_INVITATIONIdentifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor
NCT07149740Not specifiedRECRUITINGData Gathering for A10900
NCT07171541Not specifiedNOT_YET_RECRUITINGCorrelation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy
NCT07241806Not specifiedNOT_YET_RECRUITINGMeasurment of Optic Disc Parameters, RNFL Thickness and Ganglion Cell Complex in Myopic, Hypermetropic and Emmetropic Patients Using OCT and Axial Length Measurments
NCT07241845Not specifiedNOT_YET_RECRUITINGEpiretinal Membrane in Patients With DR.
NCT00926861Not specifiedUNKNOWNPosterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
NCT01080859Not specifiedCOMPLETEDVessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography
NCT01391871Not specifiedCOMPLETEDVascular Healing of DES at 3 Months
NCT01603810Not specifiedUNKNOWNEvaluating In Vivo OCT Imaging for Periocular Basal Cell Carcinoma
NCT01743274Not specifiedCOMPLETEDDoes Optical Coherence Tomography Optimise Results of Stenting
NCT02024048Not specifiedUNKNOWNEvaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography
NCT02077764Not specifiedCOMPLETEDThe GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.
NCT02234804Not specifiedUNKNOWNThe Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study
NCT02521142Not specifiedUNKNOWNNon-invasive Optical Angiography in Age-related Macular Degeneration
NCT02638025Not specifiedCOMPLETEDAnterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury
NCT02775097Not specifiedCOMPLETEDEvaluation of the Accuracy of Corneal Epithelial Thickness Mapping With SD-OCT
NCT02783963Not specifiedCOMPLETEDOptical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease
NCT02785029Not specifiedTERMINATEDOptical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)
NCT03106961Not specifiedUNKNOWNOCT and Scaffold Embedding After NC Balloon
NCT03176810Not specifiedUNKNOWNComparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention
NCT03229993Not specifiedCOMPLETEDOCT in Borderline Coronary Artery Lesions
NCT03377075Not specifiedCOMPLETEDStudy of the Choroidal and Retinal Thickness in Relation to Axial Length.
NCT03489915Not specifiedUNKNOWNCorrelation Between the Visual Acuity & the OCT Pattern of Macular Edema Secondary to RVO
NCT03679156Not specifiedCOMPLETEDRetinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor
NCT03680326Not specifiedCOMPLETEDIntravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
NCT03893474Not specifiedUNKNOWNQuality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
NCT03939299Not specifiedUNKNOWNOCT Explores Vascular Response and Healing Profile After Stenting in CTO
NCT04047485Not specifiedUNKNOWNEvaluation of the Effect of Cataract Surgery on Cognitive Function in Very Elderly Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

MoleculeSourceStatusShared targets
CALCIPOTRIENEChEMBLPhase 4 (approved)VDR
CALCITRIOLChEMBLPhase 4 (approved)VDR
CHOLECALCIFEROLChEMBLPhase 4 (approved)VDR
DOXERCALCIFEROLChEMBLPhase 4 (approved)VDR
TACALCITOLChEMBLPhase 4 (approved)VDR
CURCUMINChEMBLPhase 3VDR
SEOCALCITOLChEMBLPhase 3VDR
TAUROLITHOCHOLIC ACIDChEMBLPhase 3VDR
chenodiolPubChemApprovedVDR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot